GlassScriptPhysician profile
Sharad Kumar Dass
NPI 1144312125
$17,745.16
in general payments reported to CMS, 2019-2025
28 companies · $804 in 2025
The $804 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,654 · 2020: $174 · 2021: $626 · 2022: $690 · 2023: $13K · 2024: $618 · 2025: $804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $9,001 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,000 · Food and Beverage: $2,380 · Travel and Lodging: $219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $9,000.94 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,000.00 |
| Food and Beverage | $2,380.21 |
| Travel and Lodging | $219.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $12,268.46 | 2023-2025 | Da Vinci Surgical System, Ion, Da Vinci Sp |
| Veran Medical Technologies, INC. | $818.91 | 2019 | |
| Glaxosmithkline, LLC. | $669.82 | 2022-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $665.23 | 2022-2025 | Fasenra |
| Novo Nordisk INC | $476.85 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $298.98 | 2019-2025 | |
| Merit Medical Systems INC | $288.49 | 2023 | Aero Stent and Delivery System, Aeromini Stent and Delivery System |
| Amarin Pharma, INC. | $258.91 | 2019 | |
| Insmed, INC. | $197.57 | 2024-2025 | Arikayce, Brinsupri |
| La Jolla Pharmaceutical Company | $186.81 | 2023 | Giapreza |
| Medtronic, INC. | $173.60 | 2021 | |
| Verona Pharma, INC. | $152.63 | 2025 | Ohtuvayre |
| Janssen Pharmaceuticals, INC | $152.15 | 2020 | |
| Stryker Corporation | $148.91 | 2025 | Surgicount, Neptune |
| Allergan, INC. | $136.89 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $125.00 | 2023 | Ubrelvy, Qulipta |
| Actelion Pharmaceuticals US, INC. | $124.99 | 2025 | Opsumit, Uptravi |
| Portola Pharmaceuticals, LLC | $124.99 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $123.51 | 2024 | Inpefa |
| Novartis Pharmaceuticals Corporation | $118.93 | 2019 | |
| Mallinckrodt Hospital Products INC. | $77.40 | 2021 | |
| Harmony Biosciences LLC | $45.10 | 2022 | |
| Lilly USA, LLC | $28.19 | 2025 | Zepbound |
| Inspire Medical Systems, INC. | $23.77 | 2025 | Inspire |
| Vifor Pharma, INC. | $20.79 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.86 | 2021 | |
| Gilead Sciences, INC. | $12.72 | 2019 | |
| Merck Sharp & Dohme LLC | $12.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharad Dass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.